SCHEMBL4775414

SCHEMBL4775414

O=C(O)N[C@H](COCc1ccccc1)C(=O)Nc1cc2c3c(c[nH]c3c1)C=NNC2=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 1/20 0.53
AURKA O14965 1/20 0.53
MAPK13 O15264 1/20 0.53
PDPK1 O15530 1/20 0.53
JAK2 O60674 1/20 0.53
ROCK2 O75116 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
CHEK2 O96017 1/20 0.53
ABL1 P00519 1/20 0.53
EGFR P00533 1/20 0.53
PRKCG P05129 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
CDK1 P06493 1/20 0.53
RET P07949 1/20 0.53
ROS1 P08922 1/20 0.53
KIT P10721 1/20 0.53
PIM1 P11309 1/20 0.53
FGFR1 P11362 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13987258 0.90 PLK4 (0.48) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL13987307 0.88 ROCK1 (0.54) PLK4AURKAMAPK13PDPK1JAK2
Hydrochloric Acid SCHEMBL4780398 0.87 ROCK2 (0.53) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL4811050 0.83 PLK4 (0.52) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL5447724 0.83 AURKA (0.49) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL4780382 0.81 PLK4 (0.50) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL13987826 0.81 ROCK2 (0.56) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL4778277 0.78 ROCK2 (0.56) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL4815437 0.77 ROCK2 (0.61) PLK4AURKAMAPK13PDPK1JAK2
SCHEMBL14144135 0.76 AURKA (0.49) PLK4AURKAMAPK13PDPK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462713-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 US disclosed
EP-1947102-A1 Compositions comprising diazepinoindole derivatives as kinase inhibitors Pfizer, Inc. (US) 2008-07-23 EP disclosed
US-6967198-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS INC. (US) 2005-11-22 US disclosed